Two healthcare stocks that may or may not be boring, but that regardless look like strong growth stocks to invest in this ...

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

Biogen’s disappointing Leqembi performance and weak pipeline hurt future growth. Learn why BIIB stock is rated "sell" due to ...

If big pharma was hoping that there would not be drug price negotiations under President Trump, they seem to have had their hopes dashed. That ...

Resmed has its origins in the 1980s, when Sydney sleep expert Dr Colin Sullivan converted a vacuum cleaner to deal with the ...

If you believe in the Efficient Market hypothesis, you had a good week. Despite a hotter-than-expected CPI print, a rise in credit card delinquencies, and the Trump administration’s announcement of 25 ...

A new study adds to a growing body of research suggesting a potential link between popular GLP-1 medications like Ozempic and vision loss.

Amazon Music and WPP unveiled Louder Than Cancer, an effort uniting top global artists to harness the power of music in recognition of World Cancer Day with creative leadership from WPP’s Grey Health, ...

CEO Richard Francis reflects on Teva’s return to growth during his tenure, and what’s next for the drugmaker in its quest to ...

Incyte Corporation INCY reported fourth-quarter 2024 adjusted earnings of $1.43 per share, which missed the Zacks Consensus ...

The price a stock trades at can drastically impact your overall returns. If you wait for a top growth stock to come down to a ...

Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.